Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 61 results for heparin

  1. Intrapartum care for women with existing medical conditions or obstetric complications and their babies (NG121)

    This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.

  2. PROPATEN heparin-bonded vascular graft for peripheral arterial disease (MIB42)

    NICE has developed a medtech innovation briefing (MIB) on the PROPATEN heparin-bonded vascular graft for peripheral arterial disease

  3. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

  4. Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)

    Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.

  5. Venous thromboembolism in adults (QS201)

    This quality standard covers reducing the risk of venous thromboembolism (VTE) in people aged 16 and over who are in hospital. It also covers diagnosing and treating VTE in all people aged 18 and over. It describes high-quality care in priority areas for improvement.

  6. Perioperative care in adults (NG180)

    This guideline covers care for adults (aged 18 and over) having elective or emergency surgery, including dental surgery. It covers all phases of perioperative care, from the time people are booked for surgery until they are discharged afterward. The guideline includes recommendations on preparing for surgery, keeping people safe during surgery and pain relief during recovery.

  7. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

    Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.

  8. High-sensitivity troponin tests for the early rule out of NSTEMI (DG40)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction)

  9. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.

  10. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

    This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

  11. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  12. Further research on the clinical effectiveness of rivaroxaban compared with low molecular weight heparin (LMWH) in patients with active cancer should be conducted.

    clinical effectiveness of rivaroxaban compared with low molecular weight heparin (LMWH) in patients with active cancer should be...

  13. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)

    This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer.

  14. Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

    Evidence-based recommendations on using thrombolytic drugs (alteplase [Actilyse], reteplase [Rapilysin], streptokinase [Streptase] and tenecteplase [Metalyse]) for treating acute myocardial infarction in adults.